S. Yao

发表

Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer.

J. Nemunaitis, M. Edelman, J. Stephenson, 2014, Lung cancer.

Use of Hormonal Therapy in Men With Metastatic Prostate Cancer

R. DiPaola, S. Yao, G. Lu-Yao, 2006 .

Prostate Cancer Chemoprevention

S. Yao, J. Drisko, 2004 .

The science and art of prostate cancer screening.

S. Yao, G. Lu-Yao, 2011, Journal of the National Cancer Institute.

Population based study of hormonal therapy and survival in men with metastatic prostate cancer.

R. DiPaola, S. Yao, G. Lu-Yao, 2007, The Journal of urology.

Outcomes of treatment vs observation of localized prostate cancer in elderly men.

M. Barry, P. Albertsen, S. Yao, 2007, JAMA.

Does primary androgen-deprivation therapy delay the receipt of secondary cancer therapy for localized prostate cancer?

R. DiPaola, W. Shih, Yong Lin, 2012, European urology.

EDITORIALS Understanding and Appreciating Overdiagnosis in the

S. Yao, G. Lu-Yao, 2002 .

Understanding and appreciating overdiagnosis in the PSA era.

S. Yao, G. Lu-Yao, 2002, Journal of the National Cancer Institute.

Changing patterns in competing causes of death in men with prostate cancer: a population based study.

T. Stukel, S. Yao, G. Lu-Yao, 2004, The Journal of urology.

An evidence-based approach to prostate cancer follow-up.

R. DiPaola, S. Yao, 2003, Seminars in oncology.

Primary Androgen Deprivation Therapy in Men With Prostate Cancer To the Editor: The analysis of prostate cancer-specific and overallsurvivalbyDrLu-Yaoandcolleagues 1 concludedthat

W. Shih, S. Yao, G. Lu-Yao, 2017 .

Failure to report financial disclosure information.

W. Shih, P. Albertsen, S. Yao, 2009, JAMA.

Primary Androgen Deprivation Therapy in Men With Prostate Cancer—Reply

W. Shih, S. Yao, G. Lu-Yao, 2009 .

A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies

J. Nemunaitis, P. Kirschmeier, Ying‐Ming Jou, 2013, Journal of Translational Medicine.

A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma

M. Ayers, S. Bielack, C. Herzog, 2016, Pediatric blood & cancer.

Age and Prostate Cancer Survival—Reply

P. Albertsen, S. Yao, G. Lu-Yao, 2010 .

Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer.

S. Doyle-Lindrud, R. DiPaola, J. Nemunaitis, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I.

C. Fuchs, P. Deutsch, Sunil Sharma, 2002, Molecular cancer therapeutics.

Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer.

C. Shapiro, M. Mita, A. Mita, 2014, Clinical breast cancer.

A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of SCH 727965, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies.

J. Nemunaitis, P. Kirschmeier, D. Khaira, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes of localized prostate cancer following conservative management.

Dirk F Moore, Michael J Barry, Peter C Albertsen, 2009, JAMA.

Survival following primary androgen deprivation therapy among men with localized prostate cancer.

Dirk F Moore, Peter C Albertsen, R. DiPaola, 2008, JAMA.

Population-based study of long-term survival in patients with clinically localised prostate cancer

S. Yao, G. Lu-Yao, Lu-Yao L. Grace, 1997, The Lancet.

A phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the novel cyclin-dependent kinase inhibitor SCH 727965 administered every 3 weeks in subjects with advanced malignancies

Jennifer L Moseley, G. Shapiro, C. Takimoto, 2008 .

Prostate-specific antigen screening in elderly men.

T. Stukel, S. Yao, G. Lu-Yao, 2003, Journal of the National Cancer Institute.

Interval after prostate specific antigen testing and subsequent risk of incurable prostate cancer.

S. Yao, G. Lu-Yao, Lu-Yao L. Grace, 2001, The Journal of urology.

A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies.

S. Soignet, P. Deutsch, C. Britten, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Effect of age and surgical approach on complications and short-term mortality after radical prostatectomy--a population-based study.

P. Albertsen, S. Yao, G. Lu-Yao, 1999, Urology.

Population-based study of relationships between hospital volume of prostatectomies, patient outcomes, and length of hospital stay.

S. Yao, G. Lu-Yao, Grace L. Lu-Yao, 1999, Journal of the National Cancer Institute.

Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate Cancer.

R. DiPaola, Yong Lin, P. Albertsen, 2015, European urology.

Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer.

R. DiPaola, W. Shih, Yong Lin, 2014, JAMA internal medicine.

Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib

J. Cortes, M. Deininger, G. Verhoef, 2020 .

A randomized, phase II study of the anti-insulin-like growth factor receptor type 1 (IGF-1R) monoclonal antibody robatumumab (SCH 717454) in patients with advanced colorectal cancer

H. Lenz, E. Lin, J. Knost, 2014, Cancer medicine.

Results of a Phase 1 Dose-Ranging Trial, and Design of a Phase 2 Trial, of K0706, a Novel C-Abl Tyrosine Kinase Inhibitor for Parkinson’s Disease. (P2.8-047)

A. Goldfine, S. Yao, O. Omidvar, 2019 .

Intravenous pegylated liposomal prednisolone outperforms intramuscular methylprednisolone in treating rheumatoid arthritis flares: A randomized controlled clinical trial

J. Bijlsma, J. V. van Laar, C. Wortel, 2021, Journal of Controlled Release.

Prevalence of vitamin B12 deficiency among geriatric outpatients.

S. Yao, G. Yao, Y. Yao, 1992, The Journal of family practice.

Abstract 2242: A randomized phase 2 study of the cyclin-dependent kinase (CDK) inhibitor Dinaciclib (SCH 727965) in patients with non-small cell lung cancer (NSCLC)

J. Nemunaitis, M. Edelman, J. Stephenson, 2011 .

Use of radical prostatectomy among Medicare beneficiaries before and after the introduction of prostate specific antigen testing.

M. Friedman, S. Yao, G. Lu-Yao, 1997, The Journal of urology.

Reply from Authors re: Karim Fizazi. Who Should Receive Androgen Deprivation Therapy? Eur Urol 2012;62:973–4: Overcoming Patient Selection Bias in Observational Studies

P. Albertsen, S. Yao, G. Lu-Yao, 2012 .

Primary radiotherapy vs conservative management for localized prostate cancer—a population-based study

R. DiPaola, A. Zietman, W. Shih, 2015, Prostate Cancer and Prostatic Disease.

Diagnosis of localized, screen-detected, prostate cancer--crisis or opportunity?

S. Yao, G. Lu-Yao, 2010, Journal of the National Cancer Institute.

Prostate cancer

S. Yao, G. Lu-Yao, 1997, The Lancet.

Use of hormonal therapy in men with metastatic prostate cancer.

R. DiPaola, S. Yao, G. Lu-Yao, 2005, The Journal of urology.